Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Schöffski, Patrick; Shao-Weng Tan, Daniel; Martín, Miguel; Ochoa-de-Olza, María; Sarantopoulos, John; D. Carvajal, Richard; Kyi, Chrisann; Esaki, Taito; Prawira, Amy; Akerley, Wallace; de Braud, Filippo; Hui, Rina; Zhang, Tian; A. Soo, Ross; Maur, Michela; Weickhardt, Andrew; Krauß, Jürgen; Deschler-Baier, Barbara; S. Lau, Allen; S. Samant, Tanay; A. Longmire, Tyler; Roy Chowdhury, Niladri; Sabatos-Peyton, Catherine; Patel, Nidhi; Ramesh, Radha; Hu, Tiancen; Carion, Ana; Gusenleitner, Daniel; Yerramilli-Rao, Padmaja; Askoxylakis, Vasileios; L. Kwak, Eunice; S. Hong, David

doi:10.1136/jitc-2021-003776

Public

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Published in Journal for ImmunoTherapy of Cancer • Feb 1, 2022

Authors:

Patrick Schöffski

Daniel Shao-Weng Tan

Miguel Martín

Abstract

Background Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for the treatment of patients with advanced/metastatic solid tu...

Subject

Medicine

Adverse effect

Dosing

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!